Core Viewpoint - The company reported a slight increase in net profit for 2025, driven by stable performance in its financial business, while facing challenges in its industrial operations [1][2]. Financial Business Performance - The net profit attributable to shareholders for 2025 was 3.889 billion HKD, a year-on-year increase of 0.67%, slightly below the expected 4.1 billion HKD [1]. - The net interest margin reached 4.39% in 2025, up from 4.0% in 2024, indicating improved profitability [1]. - The total net amount of interest-earning assets was 272 billion HKD at the end of 2025, representing a growth of 4.38% compared to the end of 2024 [1]. - The non-performing loan ratio improved to 1.03% at the end of 2025, better than the 1.07% recorded at the end of 2024 [1]. Inclusive Finance Business - The inclusive finance segment saw significant growth, with net interest-earning assets reaching 28.179 billion HKD, accounting for 10.4% of total interest-earning assets, up from 6.6% in 2024 [2]. - Interest income from inclusive finance increased by 125.25% year-on-year to 3.541 billion HKD, with an average asset yield of approximately 15.7% [2]. - The company implemented stricter policies for bad debt recognition, resulting in a non-performing asset balance of zero at year-end 2025 [2]. Industrial Operations Challenges - The industrial operations segment faced profitability pressure, with net profit for Hongxin Jianfa dropping by 83.6% to 147 million HKD due to increased domestic competition [2]. - Hongxin Health reported a revenue of 3.572 billion HKD, down 12.7% year-on-year, with net profit declining by 64.3% to 83 million HKD [2]. Dividend Policy - The company declared a dividend per share (DPS) of 0.56 HKD for 2025, with a payout ratio of approximately 61%, indicating a stable dividend foundation [3]. - Future dividend rates are expected to remain stable with potential for increase, despite challenges in industrial operations [3].
远东宏信(3360.HK)2025年报点评：金融业务稳健支撑丰厚分红